About IGEA Pharma N.V.

IGEA is a health-tech group focused on measure and control of identified factors related to life-threatening diseases. IGEA developed ‘ALZ-1’, a test kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of lzheimer’s and diabetes type II respectively.

IGEA is listed on the SIX Swiss Exchange under the ticker ‘IGPH’ and is headquartered in Hoofddorp, the Netherlands. The Group’s principal place of business is in the US.